Mohanty 1999.

Methods	Site not described. Randomization not described. Blinding: double‐blind
Participants	Geographic region: NR Study setting: clinic N = 75 Baseline modified Boyarsky: NR Baseline prostate volume: SR 28.78 mL; placebo 29.89 mL Mean age (range): NR (40 to 90) years Race: NR Diagnostic criteria: BPH grades I or II; symptomatic; without surgical indication; took no BPH drug treatment for last 30 days
Interventions	Control: matching placebo, 1 capsule twice daily Treatment: SR, 1 capsule twice daily Study duration: 2 months Lost to follow‐up: SR n = 2; placebo n = 0
Outcomes	Modified Boyarsky (range 0 to 27; higher score indicates worse symptoms) Frequency Nocturia Peak urine flow Residual volume Prostate size (ultrasound) Adverse events
Notes	Exclusions: men with prostate conditions other than BPH (carcinoma of the prostate, infective prostatitis); serious renal, hepatic, and cardiac conditions Full text not available for this update.